What is Lifecycle Biotechnologies?
Operating for over four decades, Lifecycle Biotechnologies serves as a critical infrastructure provider for the biopharmaceutical, molecular diagnostics, and cellular agriculture industries. The company distinguishes itself through a specialized suite of proprietary technologies, including the HELIX Oscillating Biomixer, CHEM+NECT, and CHEM+POUR systems. These tools are essential for high-precision bioprocessing and research applications. With ISO 13485:2016 and ISO 9001:2015 certifications, the firm maintains a reputation for quality and reliability, acting as a foundational partner for tissue banks and global research institutions that require stringent adherence to regulatory and manufacturing benchmarks.
How much funding has Lifecycle Biotechnologies raised?
Lifecycle Biotechnologies has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Lifecycle Biotechnologies
PPP
Public-Private Partnership
What's next for Lifecycle Biotechnologies?
With this late-stage capital injection, Lifecycle Biotechnologies is positioned to accelerate its strategic growth initiatives. The firm is expected to leverage these resources to expand its manufacturing footprint and enhance its R&D capabilities, ensuring that its product offerings remain at the forefront of the evolving life science landscape. By focusing on operational efficiency and market penetration, the company aims to solidify its role as an indispensable supplier in the global medical product supply chain, potentially exploring new applications for its biomixing and chemical handling technologies in emerging biotech sectors.
See full Lifecycle Biotechnologies company page
